Small cap biotech is dead from a retail investor standpoint, and with the price and volume at such small levels, no institution can touch it. This is one of those stocks that will muddle along until a certain milestone brings some niche institution into the market and the stock will double in a heartbeat. Assuming their technology/products holds the promise described in the recent earnings call, a double will be just the start. If they secure a meaningful partnership for Alocrest (i.e. decent money from a notable partner), that could be trigger to bring an institution in. Patience will be rewarded here, IMO.